Artificial intelligence is transforming peptide drug discovery, with billion-dollar pharma deals, generative AI design tools, and over 78 percent of recent peptide-drug conjugates using AI-optimized components. The technology stack is compressing development timelines from years to months.
The FDA has cracked down on compounded GLP-1 agonists following shortage resolutions, while Congress has introduced the SAFE Drugs Act proposing sweeping new restrictions on 503A and 503B compounding pharmacies. State regulators are following suit with tighter oversight.
The FDA's reclassification of 12 peptides from Category 2 restrictions in April 2026 has reopened the door for compounding pharmacies. With the Pharmacy Compounding Advisory Committee set to review BPC-157, TB-500, and other peptides in July, practitioners are watching closely as the regulatory landscape shifts.
GLP-1 agonist shortages have resolved, but affordability barriers persist as FDA enforcement ends compounded alternatives. The first generic liraglutide has arrived, though generic semaglutide and tirzepatide remain years away from market.
The longevity biotech sector has attracted over $13 billion in venture funding, with companies like Retro Biosciences and NewLimit raising massive rounds. Rubedo Life Sciences dosed the first GPX4 modulator patient in June 2025, advancing senolytic science into clinical reality.
The FDA's approval of oral Wegovy in December 2025 and Eli Lilly's Foundayo (orforglipron) in 2026 mark a turning point for peptide drug delivery. Combined with advances in formulation science and nasal delivery systems, the era of injection-only peptide therapies is drawing to a close.
Peptide-drug conjugates are advancing rapidly with six candidates in Phase III trials and 96 in development. Offering deeper tissue penetration and simpler manufacturing than antibody-drug conjugates, PDCs are poised to reshape targeted cancer therapy.
The global peptide therapeutics market reached $131.95 billion in 2025 and is projected to hit $334.95 billion by 2034. Fueled by GLP-1 blockbusters, oral delivery approvals, and over $7 billion in cumulative funding, the industry has entered a sustained scale-up phase led by Novo Nordisk and Eli Lilly.
Mount Sinai's PGV001 personalized peptide cancer vaccine showed durable responses across five tumor types in Phase 1, with three of six surviving patients tumor-free at five years. The results have launched three new clinical trials and validated the neoantigen vaccine approach.
Tirzepatide continues to expand beyond diabetes, with FDA approval for obstructive sleep apnea, landmark cardiovascular outcomes data from the SURPASS-CVOT trial, and positive pediatric results positioning it as a platform therapy for cardiometabolic disease.